Lindbrook Capital’s Marker Therapeutics MRKR Stock Holding History

Lindbrook Capital’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100	Closed	-$6K	–	1465
2019 Q1	$6K	Buy	+100	New	+$5.84K	﹤0.01%	1036

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lindbrook Capital's MRKR Position: Q2 2019 in Review

Lindbrook Capital sold out of Marker Therapeutics (MRKR) in Q2 2019, closing a stake of 100 shares — an estimated $6K sold.

Lindbrook Capital first reported a position in MRKR in Q1 2019 and held it in 1 quarter. The position peaked at $6K in Q1 2019. 70 funds tracked by Wall St. Rank hold MRKR as of Q2 2019.

Lindbrook Capital reported no remaining Marker Therapeutics position as of Q2 2019 after selling out during the quarter.
Lindbrook Capital sold 100 Marker Therapeutics shares in Q2 2019, an estimated $6K.
Lindbrook Capital first reported a position in Marker Therapeutics in Q1 2019 and held it in 1 quarter.
Lindbrook Capital's Marker Therapeutics position peaked at $6K in Q1 2019.
70 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2019.

Based on Lindbrook Capital's 13F filing for Q2 2019, filed 24 Jul 2019.